Entering text into the input field will update the search result below

RECEF Recce Pharmaceuticals Ltd
Stock Price & Overview

$0.460.00 (0.00%)10:51 AM 08/12/22
Pink Current Info | $USD | Market Close


Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Prev. Close

Quant Ranking


Latest Headlines

People Also Follow

Company Profile

Recce Pharmaceuticals Ltd logo
Recce Pharmaceuticals Ltd, a biotechnology company, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United States, and the United Kingdom. The company’s lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use. In addition, the company engages in R327 Intravenous which provides serious/life-threatening bacterial infections, including sepsis which is in the phase 1 trial; urinary tract infections, including urosepsis; rapid infusions sepsis in the phase 2 trial; and R327 Topical offers wound infections, including infected burns; and diabetic foot ulcer infections in Phase 2 trails. Further, the company operates various pre-clinical programs, such as Mycobacterium abscessus which is in phase 1 clinical trial; bacterial sinusitis; and additional TBA. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
  • Level 23, 180 George Street
  • Salesforce Tower
  • Sydney, NSW, 2000
  • Australia
Phone Number
61 2 9256 2505
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.